NMTC (NeuroOne Medical Technologies) EBIT: $-6.64 Mil (TTM As of Mar. 2026)


NMTC NeuroOne Medical Technologies Corp NMTC
43 GF Score
Price $3.25
GF Value $6.58
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is NeuroOne Medical Technologies EBIT?

NeuroOne Medical Technologies NMTC -4.04% 43 EBIT is $-6.64 Mil as of Mar. 2026. GuruFocus rates NMTC with a GF Score™ of 43/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 3 warning signs investors should review.

NeuroOne Medical Technologies's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-6.64 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2026 was -228.03%. NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -228.67%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. NeuroOne Medical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -25.83%.

NeuroOne Medical Technologies  (NAS:NMTC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

NeuroOne Medical Technologies's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.404 * ( 1 - 0% )/( (3.885 + 3.486)/ 2 )
=-8.404/3.6855
=-228.03 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=8.578 - 1.131 - ( 3.562 - max(0, 1.258 - 8.067+3.562))
=3.885

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=7.865 - 1.575 - ( 2.804 - max(0, 1.689 - 7.404+2.804))
=3.486

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

NeuroOne Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.344/( ( (0.471 + max(3.374, 0)) + (0.427 + max(3.026, 0)) )/ 2 )
=-8.344/( ( 3.845 + 3.453 )/ 2 )
=-8.344/3.649
=-228.67 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.662 + 1.666 + 0.177) - (1.131 + 0 + 0)
=3.374

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(2.427 + 1.867 + 0.306) - (1.575 + 0 + -0.00099999999999989)
=3.026

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

NeuroOne Medical Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-6.635/25.688
=-25.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies EBIT Related Terms

NeuroOne Medical Technologies EBIT Historical Data

* Premium members only.

The historical data trend for NeuroOne Medical Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroOne Medical Technologies EBIT Chart

NeuroOne Medical Technologies Annual Data
Trend Dec16 Dec17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.95 -10.03 -11.86 -12.09 -3.27

NeuroOne Medical Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.27 -1.49 -1.62 -1.44 -2.09

NMTC vs CTSO, CODX, PETV: EBIT Comparison

For the Medical Devices subindustry, NeuroOne Medical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NeuroOne Medical Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NeuroOne Medical Technologies's EV-to-EBIT falls into.


NMTC
43GF Score
NeuroOne Medical Technologies Corp NMTC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeuroOne Medical Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-6.64 Mil mean?
NeuroOne Medical Technologies (NMTC) has a EBIT of $-6.64 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NeuroOne Medical Technologies.
Is NeuroOne Medical Technologies' EBIT too high?
NeuroOne Medical Technologies' current EBIT is $-6.64 Mil. Overall, NeuroOne Medical Technologies has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' EBIT compare to CTSO and CODX?
NeuroOne Medical Technologies' EBIT of $-6.64 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on NeuroOne Medical Technologies. NeuroOne Medical Technologies's current EBIT is $-6.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.25 — trading 50.6% below its estimated fair value. The current EBIT is $-6.64 Mil. NeuroOne Medical Technologies' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current EBIT is $-6.64 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?

Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued. The current stock price of $3.25 is trading 50.6% below its estimated GF Value™ of $6.58. GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.

Key valuation signals for NMTC:

  • EBIT: $-6.64 Mil
  • GF Value™: $6.58 vs. price of $3.25 (50.6% below fair value)
  • GF Score™: 43/100 with 3 warning signs

No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeuroOne Medical Technologies Business Description

Address 7599 Anagram Drive, Eden Prairie, MN, USA, 55344
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
43GF Score

Get the complete analysis for NMTC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.25
Price
$6.58
GF Value